BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3151075)

  • 1. [A case of diabetic orthostatic hypotension effectively managed with L-dops (L-threo-3,4-dihydroxyphenylserine)].
    Yoshikawa H; Kawai K; Inoue S; Murayama Y; Kuzuya N; Fujita T; Koide Y; Yamashita K; Yoshizawa K; Mizusawa H
    Nihon Naika Gakkai Zasshi; 1987 Nov; 76(11):1695-700. PubMed ID: 3151075
    [No Abstract]   [Full Text] [Related]  

  • 2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W; Birkmayer G; Lechner H; Riederer P
    J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
    Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD; Cilmi KM; Mattis-Graves K
    Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.
    Azuma T; Suzuki T; Mizuno R; Tsujino S; Kishimoto S; Mizuta E; Ichikawa K
    Acta Neurol Scand; 1988 May; 77(5):409-13. PubMed ID: 3137768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
    Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
    J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical effects of oral L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in patients with Shy-Drager syndrome].
    Senda Y; Muto T; Matsuoka Y; Takahashi A; Sobue I
    Rinsho Shinkeigaku; 1987 Mar; 27(3):300-4. PubMed ID: 3111772
    [No Abstract]   [Full Text] [Related]  

  • 9. [Improvement in cardiovascular autonomic dysfunction of a patient with OPCA with L-threo-3,4-dihydroxyphenylserine].
    Fukuma A; Matsubayashi K; Kitazumi T; Otsuka K; Sadakane N; Shimada K; Ozawa T
    Nihon Naika Gakkai Zasshi; 1988 Jun; 77(6):847-51. PubMed ID: 3147311
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Akizawa T; Koshikawa S; Iida N; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M; Tubakihara Y
    Nephron; 2002 Apr; 90(4):384-90. PubMed ID: 11961396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
    Lamotte G; Holmes C; Sullivan P; Goldstein DS
    Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic orthostatic hypotension].
    Uchida K; Himei H
    Nihon Rinsho; 1991 Feb; 49 Suppl():313-5. PubMed ID: 2033821
    [No Abstract]   [Full Text] [Related]  

  • 13. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
    Suzuki T; Higa S; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
    Neurology; 1981 Oct; 31(10):1323-6. PubMed ID: 6287350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N; Koshikawa S; Akizawa T; Tsubakihara Y; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M
    Am J Nephrol; 2002; 22(4):338-46. PubMed ID: 12169865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S
    Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
    Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF
    J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-threo-3, 4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury.
    Muneta S; Iwata T; Hiwada K; Murakami E; Sato Y; Imamura Y
    Jpn Circ J; 1992 Mar; 56(3):243-7. PubMed ID: 1552652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency.
    Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Schalekamp MA
    Lancet; 1987 Nov; 2(8569):1172-5. PubMed ID: 2890807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
    Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.